Unraveling the Role of Arg4 and Arg6 in the Auto‐Inhibition Mechanism of GSK 3 β From Molecular Dynamics Simulation
Glycogen synthase kinase 3 β ( GSK 3 β ) is a multifunctional serine/threonine protein kinase that is involved in several biological processes including insulin and Wnt signaling pathways. GSK 3 β can be phosphorylated by the protein kinase B ( PKB ). The mutations of A rg4 and A rg6 to alanine at N...
Gespeichert in:
Veröffentlicht in: | Chemical biology & drug design 2014-06, Vol.83 (6), p.721-730 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Glycogen synthase kinase 3
β
(
GSK
3
β
) is a multifunctional serine/threonine protein kinase that is involved in several biological processes including insulin and Wnt signaling pathways.
GSK
3
β
can be phosphorylated by the protein kinase
B
(
PKB
). The mutations of
A
rg4 and
A
rg6 to alanine at
N
‐terminal
GSK
3
β
have been reported to impair its ability to autophosphorylate at
S
er9. Despite the extensive experimental observations, the detailed mechanism for the auto‐inhibition of
GSK
3
β
has not been rationalized at the molecular level. In this study, we have demonstrated the structural consequences of
GSK
3
β
R
4
A
and
R
6
A
mutations and the atomic changes that influenced the loss of
PKB
‐binding affinity. Molecular dynamics simulation results suggested significant loss in atomic contacts in the
R
4
A
and
R
6
A
mutant systems compared to the wild‐type system. Furthermore, we observed many notable changes (such as conformation, residues motions, hydrogen bonds, and binding free energy) in the mutated
GSK
3
β
–
PKB
complexes. Loss of binding affinity in the mutated systems rendered the decrease in
GSK
3
β
phosphorylation, which, in turn, impaired the auto‐inhibition of
GSK
3
β
. The significant outcomes obtained from this study can explain the auto‐inhibition of
GSK
3
β
and maybe facilitate type 2 diabetes mellitus researches and in developing the potent drug therapies. |
---|---|
ISSN: | 1747-0277 1747-0285 |
DOI: | 10.1111/cbdd.12286 |